CCR5: From natural resistance to a new anti-HIV strategy

Viruses

Volumn 2, Issue 2, 2010, Pages 574-600

  Lopalco, Lucia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

CCR5; HIV; Vaccine

Indexed keywords

4 [1 [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4 METHYL 4 PIPERIDINYL] 2 METHYL 1 [1 [4 (TRIFLUOROMETHYL)PHENYL]ETHYL]PIPERAZINE; AMINOOXYPENTANE RANTES; APLAVIROC; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTIBODY; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; MARAVIROC; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HGS004; PRO 140; PROTEINASE INHIBITOR; PSC RANTES; RECEPTOR ANTIBODY; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VICRIVIROC;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; AUTOIMMUNITY; CONFORMATIONAL TRANSITION; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION CONTROL; MUCOSAL IMMUNITY; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; VIRUS IMMUNITY; VIRUS TRANSMISSION;

EID: 79952074339     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2020574     Document Type: Review

References (125)

1. Lodowski, D.T.; Palczewski, K. Chemokine receptors and other G protein-coupled receptors. Curr. Opin. HIV AIDS 2009, 4, 88-95.
2. Corbeau, P.; Reynes, J. CCR5 antagonism in HIV infection: ways, effects, and side effects. Aids 2009, 23, 1931-1943.
3. Trifilo, M.J.; Bergmann, C.C.; Kuziel, W.A.; Lane, T.E. CC chemokine ligand 3 (CCL3) regulates CD8(+)-T-cell effector function and migration following viral infection. J. Virol. 2003, 77, 4004-4014.
4. Alkhatib, G. The biology of CCR5 and CXCR4. Curr. Opin. HIV AIDS 2009, 4, 96-103.
5. Gonzalez, E.; Kulkarni, H.; Bolivar, H.; Mangano, A.; Sanchez, R.; Catano, G.; Nibbs, R.J.; Freedman, B.I.; Quinones, M.P.; Bamshad, M.J.; Murthy, K.K.; Rovin, B.H.; Bradley, W.; Clark, R.A.; Anderson, S.A.; O'Connell RJ.; Agan, B.K.; Ahuja, S.S.; Bologna, R.; Sen, L.; Dolan, M.J.; Ahuja, S.K. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005, 307, 1434-1440.
6. Contento, R.L.; Molon, B.; Boularan, C.; Pozzan, T.; Manes, S.; Marullo, S.; Viola, A. CXCR4-CCR5: a couple modulating T cell functions. Proc. Natl. Acad. Sci. USA 2008, 105, 10101-10106.
7. Bacon, K.B.; Premack, B.A.; Gardner, P.; Schall, T.J. Activation of dual T cell signaling pathways by the chemokine RANTES. Science 1995, 269, 1727-1730.
8. Castellino, F.; Huang, A.Y.; Altan-Bonnet, G.; Stoll, S.; Scheinecker, C.; Germain, R.N. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006, 440, 890-895.
9. Taub, D.D.; Ortaldo, J.R.; Turcovski-Corrales, S.M.; Key, M.L.; Longo, D.L.; Murphy, W.J. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J. Leukoc. Biol. 1996, 59, 81-89.
10. Huttenrauch, F.; Pollok-Kopp, B.; Oppermann, M. G protein-coupled receptor kinases promote phosphorylation and beta-arrestin-mediated internalization of CCR5 homo- and hetero-oligomers. J. Biol. Chem. 2005, 280, 37503-37515.
11. Shideman, C.R.; Hu, S.; Peterson, P.K.; Thayer, S.A. CCL5 evokes calcium signals in microglia through a kinase-, phosphoinositide-, and nucleotide-dependent mechanism. J. Neurosci. Res. 2006, 83, 1471-1484.
12. Signoret, N.; Hewlett, L.; Wavre, S.; Pelchen-Matthews, A.; Oppermann, M.; Marsh, M. Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent. Mol. Biol. Cell 2005, 16, 902-917.
13. Mueller, A.; Kelly, E.; Strange, P.G. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood 2002, 99, 785-791.
14. Manes, S.; del Real, G.; Lacalle, R.A.; Lucas, P.; Gomez-Mouton, C.; Sanchez-Palomino, S.; Delgado, R.; Alcami, J.; Mira, E.; Martinez, A.C. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep. 2000, 1, 190-196.
15. Signoret, N.; Pelchen-Matthews, A.; Mack, M.; Proudfoot, A.E.; Marsh, M. Endocytosis and recycling of the HIV coreceptor CCR5. J. Cell Biol. 2000, 151, 1281-1294.
16. Lin, Y.L.; Mettling, C.; Portales, P.; Rouzier, R.; Clot, J.; Reynes, J.; Corbeau, P. The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5. Aids 2008, 22, 430-432.
17. Venkatesan, S.; Rose, J.J.; Lodge, R.; Murphy, P.M.; Foley, J.F. Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol. Biol. Cell 2003, 14, 3305-3324.
18. Steffens, C.M.; Hope, T.J. Localization of CD4 and CCR5 in living cells. J. Virol. 2003, 77, 4985-4991.
19. Trkola, A.; Dragic, T.; Arthos, J.; Binley, J.M.; Olson, W.C.; Allaway, G.P.; Cheng-Mayer, C.; Robinson, J.; Maddon, P.J.; Moore, J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384, 184-187.
20. Wu, L.; Gerard, N.P.; Wyatt, R.; Choe, H.; Parolin, C.; Ruffing, N.; Borsetti, A.; Cardoso, A.A.; Desjardin, E.; Newman, W.; Gerard, C.; Sodroski, J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384, 179-183.
21. Achour, L.; Scott, M.G.; Shirvani, H.; Thuret, A.; Bismuth, G.; Labbe-Jullie, C.; Marullo, S. CD4-CCR5 interaction in intracellular compartments contributes to receptor expression at the cell surface. Blood 2009, 113, 1938-1947.
22. Issafras, H.; Angers, S.; Bulenger, S.; Blanpain, C.; Parmentier, M.; Labbe-Jullie, C.; Bouvier, M.; Marullo, S. Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J. Biol. Chem. 2002, 277, 34666-34673.
23. Benkirane, M.; Jin, D.Y.; Chun, R.F.; Koup, R.A.; Jeang, K.T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J. Biol. Chem. 1997, 272, 30603-30606.
24. Mellado, M.; Rodriguez-Frade, J.M.; Vila-Coro, A.J.; de Ana, A.M.; Martinez, A.C. Chemokine control of HIV-1 infection. Nature 1999, 400, 723-724.
25. Suzuki, S.; Chuang, L.F.; Yau, P.; Doi, R.H.; Chuang, R.Y. Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells. Exp. Cell Res. 2002, 280, 192-200.
26. Hogan, C.M.; Hammer, S.M. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann. Intern. Med. 2001, 134, 978-996.
27. Reynes, J.; Portales, P.; Segondy, M.; Baillat, V.; Andre, P.; Reant, B.; Avinens, O.; Couderc, G.; Benkirane, M.; Clot, J.; Eliaou, J.F.; Corbeau, P. CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 2000, 181, 927-932.
28. Clerici, M.; Butto, S.; Lukwiya, M.; Saresella, M.; Declich, S.; Trabattoni, D.; Pastori, C.; Piconi, S.; Fracasso, C.; Fabiani, M.; Ferrante, P.; Rizzardini, G.; Lopalco, L. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. Aids 2000, 14, 2083-2092.
29. de Vries, F.P.; van Der Ende, A.; van Putten, J.P.; Dankert, J. Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens. Infect. Immun. 1996, 64, 2998-3006.
30. Quillent, C.; Oberlin, E.; Braun, J.; Rousset, D.; Gonzalez-Canali, G.; Metais, P.; Montagnier, L.; Virelizier, J.L.; Arenzana-Seisdedos, F.; Beretta, A. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998, 351, 14-18.
31. Lehner, T. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol. 2002, 23, 347-351.
32. Balotta, C.; Bagnarelli, P.; Violin, M.; Ridolfo, A.L.; Zhou, D.; Berlusconi, A.; Corvasce, S.; Corbellino, M.; Clementi, M.; Clerici, M.; Moroni, M.; Galli, M. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. Aids 1997, 11, F67-71.
33. Biti, R.; Ffrench, R.; Young, J.; Bennetts, B.; Stewart, G.; Liang, T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat. Med. 1997, 3, 252-253.
34. Theodorou, I.; Meyer, L.; Magierowska, M.; Katlama, C.; Rouzioux, C. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 1997, 349, 1219-1220.
35. Gorry, P.R.; Zhang, C.; Wu, S.; Kunstman, K.; Trachtenberg, E.; Phair, J.; Wolinsky, S.; Gabuzda, D. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet 2002, 359, 1832-1834.
36. Naif, H.M.; Cunningham, A.L.; Alali, M.; Li, S.; Nasr, N.; Buhler, M.M.; Schols, D.; de Clercq, E.; Stewart, G. A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Delta32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4. J. Virol. 2002, 76, 3114-3124.
37. Sheppard, H.W.; Celum, C.; Michael, N.L.; O'Brien, S.; Dean, M.; Carrington, M.; Dondero, D.; Buchbinder, S.P. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J. Acquir. Immune. Defic. Syndr. 2002, 29, 307-313.
38. Hutter, G.; Nowak, D.; Mossner, M.; Ganepola, S.; Mussig, A.; Allers, K.; Schneider, T.; Hofmann, J.; Kucherer, C.; Blau, O.; Blau, I.W.; Hofmann, W.K.; Thiel, E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009, 360, 692-698.
39. Stewart, G.J.; Ashton, L.J.; Biti, R.A.; Ffrench, R.A.; Bennetts, B.H.; Newcombe, N.R.; Benson, E.M.; Carr, A.; Cooper, D.A.; Kaldor, J.M. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. Aids 1997, 11, 1833-1838.
40. Meyer, L.; Magierowska, M.; Hubert, J.B.; Rouzioux, C.; Deveau, C.; Sanson, F.; Debre, P.; Delfraissy, J.F.; Theodorou, I. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. Aids 1997, 11, F73-78.
41. Telenti, A. Safety concerns about CCR5 as an antiviral target. Curr. Opin. HIV AIDS 2009, 4, 131-135.
42. Moore, J.P.; Klasse, P.J. HIV-1 pathogenesis: the complexities of the CCR5-CCL3L1 complex. Cell Host Microbe 2007, 2, 281-283.
43. Zhou, Y.; Kurihara, T.; Ryseck, R.P.; Yang, Y.; Ryan, C.; Loy, J.; Warr, G.; Bravo, R. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 1998, 160, 4018-4025.
44. Glass, W.G.; Lim, J.K.; Cholera, R.; Pletnev, A.G.; Gao, J.L.; Murphy, P.M. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 2005, 202, 1087-1098.
45. Ank, N.; Petersen, K.; Malmgaard, L.; Mogensen, S.C.; Paludan, S.R. Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2. J. Virol. 2005, 79, 9831-9841.
46. Lim, J.K.; Louie, C.Y.; Glaser, C.; Jean, C.; Johnson, B.; Johnson, H.; McDermott, D.H.; Murphy, P.M. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J. Infect. Dis. 2008, 197, 262-265.
47. Wheeler, J.; McHale, M.; Jackson, V.; Penny, M. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. Antivir. Ther. 2007, 12, 233-245.
48. Prahalad, S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun. 2006, 7, 264-268.
49. Yang, Y.F.; Mukai, T.; Gao, P.; Yamaguchi, N.; Ono, S.; Iwaki, H.; Obika, S.; Imanishi, T.; Tsujimura, T.; Hamaoka, T.; Fujiwara, H. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur. J. Immunol. 2002, 32, 2124-2132.
50. Schroder, C.; Pierson, R.N., 3rd; Nguyen, B.N.; Kawka, D.W.; Peterson, L.B.; Wu, G.; Zhang, T.; Springer, M.S.; Siciliano, S.J.; Iliff, S.; Ayala, J.M.; Lu, M.; Mudgett, J.S.; Lyons, K.; Mills, S.G.; Miller, G.G.; Singer, II; Azimzadeh, A.M.; DeMartino, J.A. CCR5 blockade modulates inflammation and alloimmunity in primates. J. Immunol. 2007, 179, 2289-2299.
51. Berson, J.F.; Doms, R.W. Structure-function studies of the HIV-1 coreceptors. Semin. Immunol. 1998, 10, 237-248.
52. Blanpain, C.; Vanderwinden, J.M.; Cihak, J.; Wittamer, V.; Le Poul, E.; Issafras, H.; Stangassinger, M.; Vassart, G.; Marullo, S.; Schlndorff, D.; Parmentier, M.; Mack, M. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol. Biol. Cell 2002, 13, 723-737.
53. Alkhatib, G.; Locati, M.; Kennedy, P.E.; Murphy, P.M.; Berger, E.A. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology 1997, 234, 340-348.
54. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R.E.; Hill, C.M.; Davis, C.B.; Peiper, S.C.; Schall, T.J.; Littman, D.R.; Landau, N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381, 661-666.
55. Dragic, T.; Litwin, V.; Allaway, G.P.; Martin, S.R.; Huang, Y.; Nagashima, K.A.; Cayanan, C.; Maddon, P.J.; Koup, R.A.; Moore, J.P.; Paxton, W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381, 667-673.
56. Gulick, R.M.; Lalezari, J.; Goodrich, J.; Clumeck, N.; DeJesus, E.; Horban, A.; Nadler, J.; Clotet, B.; Karlsson, A.; Wohlfeiler, M.; Montana, J.B.; McHale, M.; Sullivan, J.; Ridgway, C.; Felstead, S.; Dunne, M.W.; van der Ryst, E.; Mayer, H. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008, 359, 1429-1441.
57. Pope, M. Mucosal dendritic cells and immunodeficiency viruses. J. Infect. Dis. 1999, 179 (Suppl. 3), S427-430.
58. Granelli-Piperno, A.; Delgado, E.; Finkel, V.; Paxton, W.; Steinman, R.M. Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J. Virol. 1998, 72, 2733-2737.
59. Geijtenbeek, T.B.; Kwon, D.S.; Torensma, R.; van Vliet, S.J.; van Duijnhoven, G.C.; Middel, J.; Cornelissen, I.L.; Nottet, H.S.; KewalRamani, V.N.; Littman, D.R.; Figdor, C.G.; van Kooyk, Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100, 587-597.
60. Silvestri, G.; Sodora, D.L.; Koup, R.A.; Paiardini, M.; O'Neil, S.P.; McClure, H.M.; Staprans, S.I.; Feinberg, M.B. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003, 18, 441-452.
61. Grossman, Z.; Meier-Schellersheim, M.; Sousa, A.E.; Victorino, R.M.; Paul, W.E. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat. Med. 2002, 8, 319-323.
62. Berkowitz, R.D.; Alexander, S.; McCune, J.M. Causal relationships between HIV-1 coreceptor utilization, tropism, and pathogenesis in human thymus. AIDS Res. Hum. Retroviruses 2000, 16, 1039-1045.
63. Correa, R.; Munoz-Fernandez, M.A. Viral phenotype affects the thymic production of new T cells in HIV-1-infected children. Aids 2001, 15, 1959-1963.
64. Hazenberg, M.D.; Stuart, J.W.; Otto, S.A.; Borleffs, J.C.; Boucher, C.A.; de Boer, R.J.; Miedema, F.; Hamann, D. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000, 95, 249-255.
65. van Rij, R.P.; Hazenberg, M.D.; van Benthem, B.H.; Otto, S.A.; Prins, M.; Miedema, F.; Schuitemaker, H. Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution. AIDS Res. Hum. Retroviruses 2003, 19, 389-398.
66. Moore, J.P.; Kitchen, S.G.; Pugach, P.; Zack, J.A. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 2004, 20, 111-126.
67. Margolis, L.; Shattock, R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat. Rev. Microbiol. 2006, 4, 312-317.
68. Bomsel, M.; Alfsen, A. Entry of viruses through the epithelial barrier: pathogenic trickery. Nat. Rev. Mol. Cell Biol. 2003, 4, 57-68.
69. Klasse, P.J.; Shattock, R.; Moore, J.P. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu. Rev. Med. 2008, 59, 455-471.
70. Bourinbaiar, A.S.; Metadilogkul, O.; Jirathitikal, V. Mucosal AIDS vaccines. Viral Immunol. 2003, 16, 427-445.
71. Lehner, T. Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine 2003, 21 (Suppl. 2), S68-76.
72. Verani, A.; Lusso, P. Chemokines as natural HIV antagonists. Curr. Mol. Med. 2002, 2, 691-702.
73. Neutra, M.R.; Kozlowski, P.A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 2006, 6, 148-158.
74. Niess, J.H.; Brand, S.; Gu, X.; Landsman, L.; Jung, S.; McCormick, B.A.; Vyas, J.M.; Boes, M.; Ploegh, H.L.; Fox, J.G.; Littman, D.R.; Reinecker, H.C. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005, 307, 254-258.
75. Rescigno, M.; Urbano, M.; Valzasina, B.; Francolini, M.; Rotta, G.; Bonasio, R.; Granucci, F.; Kraehenbuhl, J.P.; Ricciardi-Castagnoli, P. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2001, 2, 361-367.
76. Sanders, R.W.; de Jong, E.C.; Baldwin, C.E.; Schuitemaker, J.H.; Kapsenberg, M.L.; Berkhout, B. Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J. Virol. 2002, 76, 7812-7821.
77. Hladik, F.; McElrath, M.J. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 2008, 8, 447-457.
78. Mascola, J.R.; Frankel, S.S.; Broliden, K. HIV-1 entry at the mucosal surface: role of antibodies in protection. Aids 2000, 14 (Suppl. 3), S167-174.
79. Bouhlal, H.; Latry, V.; Requena, M.; Aubry, S.; Kaveri, S.V.; Kazatchkine, M.D.; Belec, L.; Hocini, H. Natural antibodies to CCR5 from breast milk block infection of macrophages and dendritic cells with primary R5-tropic HIV-1. J. Immunol. 2005, 174, 7202-7209.
80. Clerici, M., Butto, S, Lukwiya, M, Saresella, M, Declich, S, Trabattoni, D, Pastori, C, Piconi, S, Fracasso, C, Fabiani, M, Ferrante, P, Rizzardini, G, Lopalco, L. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS 2000 14, 2083-2092.
81. Barassi, C.; Soprana, E.; Pastori, C.; Longhi, R.; Buratti, E.; Lillo, F.; Marenzi, C.; Lazzarin, A.; Siccardi, A.G.; Lopalco, L. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J. Virol. 2005, 79, 6848-6858.
82. Barassi, C.; Lazzarin, A.; Lopalco, L. CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood 2004, 104, 2205-2206.
83. Wang, Y.; Underwood, J.; Vaughan, R.; Harmer, A.; Doyle, C.; Lehner, T. Allo-immunization elicits CCR5 antibodies, SDF-1 chemokines, and CD8-suppressor factors that inhibit transmission of R5 and X4 HIV-1 in women. Clin. Exp. Immunol. 2002, 129, 493-501.
84. Stott, E.J. Anti-cell antibody in macaques. Nature 1991, 353, 393.
85. Russo, S.; Lopalco, L. Is autoimmunity a component of natural immunity to HIV? Curr. HIV Res. 2006, 4, 177-190.
86. Pastori, C.; Weiser, B.; Barassi, C.; Uberti-Foppa, C.; Ghezzi, S.; Longhi, R.; Calori, G.; Burger, H.; Kemal, K.; Poli, G.; Lazzarin, A.; Lopalco, L. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood 2006, 107, 4825-4833.
87. Oxman, M.N. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J. Am. Osteopath. Assoc. 2009, 109, S13-17.
88. Wolinsky, S.M.; Veazey, R.S.; Kunstman, K.J.; Klasse, P.J.; Dufour, J.; Marozsan, A.J.; Springer, M.S.; Moore, J.P. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 2004, 328, 19-29.
89. Moore, J.P.; Kuritzkes, D.R. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 2009, 4, 118-124.
90. Olson, W.C.; Jacobson, J.M. CCR5 monoclonal antibodies for HIV-1 therapy. Curr. Opin. HIV AIDS 2009, 4, 104-111.
91. Heredia, A.; Gilliam, B.; Latinovic, O.; Le, N.; Bamba, D.; Devico, A.; Melikyan, G.B.; Gallo, R.C.; Redfield, R.R. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 2007, 51, 2489-2496.
92. Nabatov, A.A.; Pollakis, G.; Linnemann, T.; Paxton, W.A.; de Baar, M.P. Statins disrupt CCR5 and RANTES expression levels in CD4+ T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PLoS One 2007, 2, e470.
93. Qin, X.F.; An, D.S.; Chen, I.S.; Baltimore, D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA 2003, 100, 183-188.
94. Gonzalez, M.A.; Serrano, F.; Llorente, M.; Abad, J.L.; Garcia-Ortiz, M.J.; Bernad, A. A hammerhead ribozyme targeted to the human chemokine receptor CCR5. Biochem. Biophys. Res. Commun. 1998, 251, 592-596.
95. Steinberger, P.; Andris-Widhopf, J.; Buhler, B.; Torbett, B.E.; Barbas, C.F., 3rd Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc. Natl. Acad. Sci. USA 2000, 97, 805-810.
96. Yang, A.G.; Bai, X.; Huang, X.F.; Yao, C.; Chen, S. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc. Natl. Acad. Sci. USA 1997, 94, 11567-11572.
97. Tsibris, A.M.; Sagar, M.; Gulick, R.M.; Su, Z.; Hughes, M.; Greaves, W.; Subramanian, M.; Flexner, C.; Giguel, F.; Leopold, K.E.; Coakley, E.; Kuritzkes, D.R. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 2008, 82, 8210-8214.
98. Ogert, R.A.; Wojcik, L.; Buontempo, C.; Ba, L.; Buontempo, P.; Ralston, R.; Strizki, J.; Howe, J.A. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373, 387-399.
99. Mosier, D.E. How HIV changes its tropism: evolution and adaptation? Curr. Opin. HIV AIDS 2009, 4, 125-130.
100. Borggren, M.; Repits, J.; Kuylenstierna, C.; Sterjovski, J.; Churchill, M.J.; Purcell, D.F.; Karlsson, A.; Albert, J.; Gorry, P.R.; Jansson, M. Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression. Retrovirology 2008, 5, 28.
101. Repits, J.; Sterjovski, J.; Badia-Martinez, D.; Mild, M.; Gray, L.; Churchill, M.J.; Purcell, D.F.; Karlsson, A.; Albert, J.; Fenyo, E.M.; Achour, A.; Gorry, P.R.; Jansson, M. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology 2008, 379, 125-134.
102. Low, A.J.; Marchant, D.; Brumme, C.J.; Brumme, Z.L.; Dong, W.; Sing, T.; Hogg, R.S.; Montaner, J.S.; Gill, V.; Cheung, P.K.; Harrigan, P.R. CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res. Hum. Retroviruses 2008, 24, 219-228.
103. Huang, W.; Eshleman, S.H.; Toma, J.; Fransen, S.; Stawiski, E.; Paxinos, E.E.; Whitcomb, J.M.; Young, A.M.; Donnell, D.; Mmiro, F.; Musoke, P.; Guay, L.A.; Jackson, J.B.; Parkin, N.T.; Petropoulos, C.J. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J. Virol. 2007, 81, 7885-7893.
104. Richman, D.D.; Wrin, T.; Little, S.J.; Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 2003, 100, 4144-4149.
105. Pugach, P.; Ketas, T.J.; Michael, E.; Moore, J.P. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 2008, 377, 401-407.
106. Trkola, A.; Ketas, T.J.; Nagashima, K.A.; Zhao, L.; Cilliers, T.; Morris, L.; Moore, J.P.; Maddon, P.J.; Olson, W.C. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 2001, 75, 579-588.
107. Jacobson, J.M.; Saag, M.S.; Thompson, M.A.; Fischl, M.A.; Liporace, R.; Reichman, R.C.; Redfield, R.R.; Fichtenbaum, C.J.; Zingman, B.S.; Patel, M.C.; Murga, J.D.; Pemrick, S.M.; D'Ambrosio, P.; Michael, M.; Kroger, H.; Ly, H.; Rotshteyn, Y.; Buice, R.; Morris, S.A.; Stavola, J.J.; Maddon, P.J.; Kremer, A.B.; Olson, W.C. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J. Infect. Dis. 2008, 198, 1345-1352.
108. Lalezari, J.; Yadavalli, G.K.; Para, M.; Richmond, G.; Dejesus, E.; Brown, S.J.; Cai, W.; Chen, C.; Zhong, J.; Novello, L.A.; Lederman, M.M.; Subramanian, G.M. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J. Infect. Dis. 2008, 197, 721-727.
109. Rusconi, S.; La Seta-Catamancio, S.; Kurtagic, S.; Galazzi, M.; Arienti, D.; Trabattoni, D.; Wilken, J.; Thompson, D.A.; Offord, R.E.; Galli, M.; Clerici, M. Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation. AIDS Res. Hum. Retroviruses 1999, 15, 861-867.
110. Mack, M.; Luckow, B.; Nelson, P.J.; Cihak, J.; Simmons, G.; Clapham, P.R.; Signoret, N.; Marsh, M.; Stangassinger, M.; Borlat, F.; Wells, T.N.; Schlondorff, D.; Proudfoot, A.E. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 1998, 187, 1215-1224.
111. Gaertner, H.; Cerini, F.; Escola, J.M.; Kuenzi, G.; Melotti, A.; Offord, R.; Rossitto-Borlat, I.; Nedellec, R.; Salkowitz, J.; Gorochov, G.; Mosier, D.; Hartley, O. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. USA 2008, 105, 17706-17711.
112. Veazey, R.S.; Ling, B.; Green, L.C.; Ribka, E.P.; Lifson, J.D.; Piatak, M., Jr.; Lederman, M.M.; Mosier, D.; Offord, R.; Hartley, O. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J. Infect. Dis. 2009, 199, 1525-1527.
113. Mosier, D.E.; Picchio, G.R.; Gulizia, R.J.; Sabbe, R.; Poignard, P.; Picard, L.; Offord, R.E.; Thompson, D.A.; Wilken, J. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 1999, 73, 3544-3550.
114. Lopalco, L.; Pastori, C.; Cosma, A.; Burastero, S.E.; Capiluppi, B.; Boeri, E.; Beretta, A.; Lazzarin, A.; Siccardi, A.G. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res. Hum. Retroviruses 2000, 16, 109-115.
115. Chain, B.M.; Noursadeghi, M.; Gardener, M.; Tsang, J.; Wright, E. HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor. Vaccine 2008, 26, 5752-5759.
116. Devito, C.; Zuber, B.; Schroder, U.; Benthin, R.; Okuda, K.; Broliden, K.; Wahren, B.; Hinkula, J. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol. 2004, 173, 7078-7089.
117. Buratti, E.; McLain, L.; Tisminetzky, S.; Cleveland, S.M.; Dimmock, N.J.; Baralle, F.E. The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J. Gen Virol. 1998, 79 (Pt 11), 2709-2716.
118. Pastori, C.; Clivio, A.; Diomede, L.; Consonni, R.; De Mori, G.M.; Longhi, R.; Colombo, G.; Lopalco, L. Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens. J. Virol. 2008, 82, 4125-4134.
119. Chackerian, B.; Lowy, D.R.; Schiller, J.T. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc. Natl. Acad. Sci. USA 1999, 96, 2373-2378.
120. Bogers, W.M.; Bergmeier, L.A.; Ma, J.; Oostermeijer, H.; Wang, Y.; Kelly, C.G.; Ten Haaft, P.; Singh, M.; Heeney, J.L.; Lehner, T. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. Aids 2004, 18, 25-36.
121. Misumi, S.; Nakayama, D.; Kusaba, M.; Iiboshi, T.; Mukai, R.; Tachibana, K.; Nakasone, T.; Umeda, M.; Shibata, H.; Endo, M.; Takamune, N.; Shoji, S. Effects of immunization with CCR5-based cycloimmunogen on simian/HIVSF162P3 challenge. J. Immunol. 2006, 176, 463-471.
122. Fauci, A. Pathogenesis of HIV disease: opportunities for new prevention interventions. Clinical Infectious Diseases 2007, 45, S206-S212.
123. Paxton, W.A.; Kang, S. Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression. Semin. Immunol. 1998, 10, 187-194.
124. Wu, L.; Paxton, W.A.; Kassam, N.; Ruffing, N.; Rottman, J.B.; Sullivan, N.; Choe, H.; Sodroski, J.; Newman, W.; Koup, R.A.; Mackay, C.R. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 1997, 185, 1681-1691.
125. Fatkenheuer, G.; Nelson, M.; Lazzarin, A.; Konourina, I.; Hoepelman, A.I.; Lampiris, H.; Hirschel, B.; Tebas, P.; Raffi, F.; Trottier, B.; Bellos, N.; Saag, M.; Cooper, D.A.; Westby, M.; Tawadrous, M.; Sullivan, J.F.; Ridgway, C.; Dunne, M.W.; Felstead, S.; Mayer, H.; van der Ryst, E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 2008, 359, 1442-1455.